The potential benefits of ADAM17 inhibition on increasing neutrophil infiltration at sites of infection and reducing damaging inflammation may be exploited in clinical settings to reduce sepsis progression as well as its occurrence in high risk, general surgery patients. The gene discussed is ADAM17; the disease is Sepsis.